Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Non-Current Deffered Revenue (2017 - 2018)

Gsk has reported Non-Current Deffered Revenue over the past 2 years, most recently at $24.4 million for Q4 2018.

  • Quarterly results put Non-Current Deffered Revenue at $24.4 million for Q4 2018, down 16.3% from a year ago — trailing twelve months through Dec 2018 was $24.4 million (down 16.3% YoY), and the annual figure for FY2018 was $25.4 million, down 10.46%.
  • Non-Current Deffered Revenue for Q4 2018 was $24.4 million at Gsk, down from $29.2 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for GLAXF hit a ceiling of $29.2 million in Q4 2017 and a floor of $24.4 million in Q4 2018.